AbbVie 2014 Annual Report Download - page 122
Download and view the complete annual report
Please find page 122 of the 2014 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112 -
113 -
114 -
115 -
116 -
117 -
118 -
119 -
120 -
121 -
122 -
123 -
124 -
125 -
126 -
127 -
128 -
129 -
130 -
131 -
132 -
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
 |
 |
17MAR201515325913
13FEB201501375473
13NOV201221352027
Performance Highlights. In 2014, AbbVie continued to deliver on our commitment to stockholders by growing
our sales and earnings, significantly increasing our quarterly dividend, and delivering top quartile returns. The measures
set forth below were calculated as of December 31, 2014.
7.1% Adjusted operaonal sales growth vs. 2013*
Delivered growth a year ahead of schedule
22.5% Increase in quarterly dividend since AbbVie launch
Raised quarterly dividend to $0.49 per share from $0.40 per share at separaon
$49BN Increase in market cap since AbbVie launch
Added significant stockholder value with a market cap over $100 billion
105.7% 2-year total shareholder return since 2013 incepon
28% total shareholder return in 2014
5.7% Adjusted earnings per share growth vs. 2013*
Significantly outperformed original guidance to deliver 2014 adjusted EPS of $3.32/share
40+ Acve clinical development programs
Most robust pipeline in company history
*Adjusted sales and adjusted earnings per share are reported and reconciled in our
Form 8-K dated January 30, 2015.
Additional Highlights:
• In 2014, AbbVie delivered Humira sales of $12.5 billion, an increase of nearly 19% compared to 2013 on a
constant currency basis. Humira’s performance was driven by market growth across therapeutic categories
and geographies, approval of new indications, and market share gains. Sales growth also was driven by
strong performance from other key brands including Synagis, Synthroid, Creon and Duodopa.
• In December 2014, we secured U.S. Food and Drug Administration (FDA) approval for our interferon-free
HCV regimen, Viekira Pak.
• With a record number of programs currently in mid- and late-stage development spanning large and growing
specialty categories, in 2014 we continued to advance our compelling R&D pipeline. This includes numerous
data and regulatory milestones and phase transitions.
• We further enhanced our pipeline by announcing a strategic collaboration with Infinity Pharmaceuticals, Inc.
to develop and commercialize duvelisib (IPI-145) for the treatment of blood cancers, and we entered into a
novel R&D collaboration with Calico Life Sciences LLC, a life sciences company backed by Google Inc., to
discover, develop, and bring to market new therapies for patients with age-related diseases.
22015 Proxy Statement
PROXY STATEMENT SUMMARY